NEW YORK (GenomeWeb News) – Cancer Genetics has received CLIA and New York State approvals for the clinical use of its mature B-cell neoplasm array, or MatBA, for diffuse large B-cell lymphoma, the company said late Monday.

The MatBA-DLBCL array is to assist clinicians in the diagnosis and prognosis of DLBCL.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.